Equities analysts expect BioScrip Inc (NASDAQ:BIOS) to announce ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for BioScrip’s earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.09). BioScrip also posted earnings per share of ($0.12) during the same quarter last year. The company is scheduled to issue its next earnings results on Thursday, May 9th.

On average, analysts expect that BioScrip will report full-year earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.32) to ($0.14). For the next year, analysts anticipate that the firm will post earnings of ($0.19) per share, with EPS estimates ranging from ($0.21) to ($0.17). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover BioScrip.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Friday, March 15th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.11). The firm had revenue of $183.57 million for the quarter, compared to analyst estimates of $188.39 million. BioScrip’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.03) EPS.

A number of equities research analysts have recently commented on the stock. TheStreet downgraded shares of BioScrip from a “c-” rating to a “d” rating in a report on Wednesday, April 3rd. BidaskClub upgraded shares of BioScrip from a “hold” rating to a “buy” rating in a report on Friday, January 11th. Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Stephens downgraded shares of BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 price target for the company. in a report on Monday, March 18th. Finally, Canaccord Genuity lowered their price target on shares of BioScrip from $5.00 to $3.50 and set a “buy” rating for the company in a report on Monday, March 18th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. BioScrip has an average rating of “Hold” and an average price target of $4.70.

A number of institutional investors have recently added to or reduced their stakes in BIOS. Maven Securities LTD purchased a new stake in BioScrip in the fourth quarter valued at approximately $45,000. Caxton Associates LP purchased a new stake in BioScrip in the fourth quarter valued at approximately $52,000. Virtu Financial LLC grew its holdings in BioScrip by 60.6% in the fourth quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after purchasing an additional 6,868 shares during the period. Menta Capital LLC purchased a new stake in BioScrip in the fourth quarter valued at approximately $124,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in BioScrip by 383.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock valued at $161,000 after purchasing an additional 35,700 shares during the period. Hedge funds and other institutional investors own 82.51% of the company’s stock.

Shares of NASDAQ BIOS opened at $1.73 on Friday. The stock has a market cap of $233.24 million, a PE ratio of -3.53 and a beta of 0.69. BioScrip has a 12 month low of $1.69 and a 12 month high of $4.14.

BioScrip Company Profile

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Read More: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.